Atlas Trials

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Clinical trial NCT01237951 · COMPLETED

Trial details

NCT number
NCT01237951
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myeloma
Start date
2010-11-08
Primary completion
2017-09-20
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.